Delving into the Latest Updates on Sparkbiopharma Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Nervous System Diseases

Other Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	5
Nervous System Diseases	2
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Small molecule drug	10

Top 5 Target	Count

HMGB1(High Mobility Group Protein B1)	3
STING(Stimulator of interferon genes)	1
STING x TRIM29	1

This clinical trial aims to learn about the safety, tolerability, and pharmacokinetic properties of SB17170 and its active metabolite SB1703 in single and multiple oral administration in healthy adults.
The main questions it aims to answer are the safety, tolerability, and PK characteristics of SB17170 in healthy adults.

Start Date24 May 2023

Sponsor / Collaborator

Sparkbiopharma Co., Ltd.

NCT05522868 / RecruitingPhase 1

An Open-label, Multicenter, Phase 1 Clinical Trial to Evaluate MTD, Safety, PK/PD and Preliminary Anti-tumor Activity of SB17170 in Patients With Locally Advanced or Metastatic Solid Tumors Who Have Failed Standard of Care

Phase 1 Open-label, multicenter, dose escalation, dose expansion study

Start Date17 Oct 2022

Sponsor / Collaborator

Sparkbiopharma Co., Ltd.

100 Clinical Results associated with Sparkbiopharma Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Sparkbiopharma Co., Ltd.

Login to view more data

100 Deals associated with Sparkbiopharma Co., Ltd.

Login to view more data

100 Translational Medicine associated with Sparkbiopharma Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

5

2

Preclinical

Phase 1 Clinical

2

1

Phase 2 Clinical

Other

5

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

SBP-401 ( HMGB1 )	Idiopathic Pulmonary Fibrosis More	Phase 2
SB17170 ( HMGB1 )	-	Phase 1
SBP-101(Sparkbiopharma)	Biliary Tract Neoplasms More	Phase 1
SB-24011 ( STING x TRIM29 )	Neoplasms More	Preclinical
SB-1703 ( HMGB1 )	Neoplasms More	Preclinical